207940 (Samsung Biologics Co Ltd) vs KOSPI 200 Comparison

207940

KOSPI 200

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

207940

KOSPI 200

Difference

1Y 3Y 5Y 10Y 15Y 20Y

207940

KOSPI 200

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

KOSPI 200

207940

0KHE

TMO

DHR

LONN

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Samsung Biologics Co Ltd
Glance View

Market Cap

70.5T KRW

Industry

Life Sciences Tools & Services

In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.

View Samsung Biologics Co Ltd Analysis

Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

US	P	PerkinElmer Inc LSE:0KHE	Add
US		Thermo Fisher Scientific Inc NYSE:TMO	Add
US		Danaher Corp NYSE:DHR	Add
CH		Lonza Group AG SIX:LONN	Add
US		Agilent Technologies Inc NYSE:A	Add
US		IQVIA Holdings Inc NYSE:IQV	Add
US		Mettler-Toledo International Inc NYSE:MTD	Add
CN		WuXi AppTec Co Ltd SSE:603259	Add
FR		Sartorius Stedim Biotech SA PAR:DIM	Add
US		Waters Corp NYSE:WAT	Add

US	P	PerkinElmer Inc LSE:0KHE	Select
US		Thermo Fisher Scientific Inc NYSE:TMO	Select
US		Danaher Corp NYSE:DHR	Select
CH		Lonza Group AG SIX:LONN	Select
US		Agilent Technologies Inc NYSE:A	Select
US		IQVIA Holdings Inc NYSE:IQV	Select
US		Mettler-Toledo International Inc NYSE:MTD	Select
CN		WuXi AppTec Co Ltd SSE:603259	Select
FR		Sartorius Stedim Biotech SA PAR:DIM	Select
US		Waters Corp NYSE:WAT	Select

US	P	PerkinElmer Inc LSE:0KHE	Add
US		Thermo Fisher Scientific Inc NYSE:TMO	Add
US		Danaher Corp NYSE:DHR	Add
CH		Lonza Group AG SIX:LONN	Add
US		Agilent Technologies Inc NYSE:A	Add
US		IQVIA Holdings Inc NYSE:IQV	Add
US		Mettler-Toledo International Inc NYSE:MTD	Add
CN		WuXi AppTec Co Ltd SSE:603259	Add
FR		Sartorius Stedim Biotech SA PAR:DIM	Add
US		Waters Corp NYSE:WAT	Add

HR	C	CROBEX INDX:CRBEX	Add
SA	T	Tadawul All Share INDX:TASI	Add
TH	S	SET Index INDX:SET	Add
ID	J	Jakarta Composite Index INDX:JKSE	Add
GR	A	Athens General Composite INDX:ATG	Add
BR	B	BOVESPA INDX:BVSP	Add
AR	S	S&P Merval INDX:MERV	Add
MX	M	Mexico S&P/BMV IPC INDX:MXX	Add
CZ	P	PX Prague Stock Index INDX:PX	Add
RU	M	MOEX Russia INDX:IMOEX	Add

	Franklin Covey Co NYSE:FC	22.56 USD 6.92%
	Mohawk Industries Inc NYSE:MHK	110.94 USD 4.36%
	Ardmore Shipping Corp NYSE:ASC	9.8 USD -1.21%
	ASGN Inc NYSE:ASGN	58.26 USD 4.61%
	Skyworks Solutions Inc NASDAQ:SWKS	73.04 USD 7.08%
	Weatherford International PLC NASDAQ:WFRD	48.88 USD 6.1%

207940

vs

KOSPI 200

Stocks Performance
207940 vs KOSPI 200

Performance Gap
207940 vs KOSPI 200

Performance By Year
207940 vs KOSPI 200

Competitors Performance
Samsung Biologics Co Ltd vs Peers

Samsung Biologics Co Ltd
Glance View

Company

Help

Tools

Stocks

	Johnson & Johnson NYSE:JNJ	154.14 USD -0.05%
	Bank of America Corp NYSE:BAC	43.36 USD 3.76%
	Mastercard Inc NYSE:MA	578.27 USD 1.69%
	Salesforce Inc NYSE:CRM	288.82 USD 4.87%
	Abbvie Inc NYSE:ABBV	190.07 USD 2.96%
	Home Depot Inc NYSE:HD	376.59 USD 3.83%

	Arista Networks Inc NYSE:ANET	92.32 USD 6.7%
	Visa Inc NYSE:V	355.85 USD 0.94%
	Texas Pacific Land Corp NYSE:TPL	1 341.12 USD 3.05%
	KLA Corp NASDAQ:KLAC	760.47 USD 8.45%
	Manhattan Associates Inc NASDAQ:MANH	196 USD 6.31%
	Monolithic Power Systems Inc NASDAQ:MPWR	709.23 USD 11.2%

	ServiceNow Inc NYSE:NOW	1 015.6 USD 3.63%
	Spotify Technology SA NYSE:SPOT	620.81 USD -4.23%
	EOG Resources Inc NYSE:EOG	114.06 USD 2.65%
	Monster Beverage Corp NASDAQ:MNST	61.36 USD 0.59%
	Copart Inc NASDAQ:CPRT	62.16 USD 1.04%
	Applied Materials Inc NASDAQ:AMAT	167.99 USD 7.96%

	Johnson & Johnson NYSE:JNJ	154.14 USD -0.05%
	Berkshire Hathaway Inc NYSE:BRK.A	772 100 USD 0.14%
	Bank of America Corp NYSE:BAC	43.36 USD 3.76%
	Mastercard Inc NYSE:MA	578.27 USD 1.69%
	UnitedHealth Group Inc NYSE:UNH	378.75 USD -0.5%
	Exxon Mobil Corp NYSE:XOM	109.16 USD 1.72%

207940 vs KOSPI 200

Stocks Performance 207940 vs KOSPI 200

Performance Gap 207940 vs KOSPI 200

Performance By Year 207940 vs KOSPI 200

Competitors Performance Samsung Biologics Co Ltd vs Peers

Samsung Biologics Co Ltd Glance View

Company

Help

Tools

Stocks

207940

vs

KOSPI 200

Stocks Performance
207940 vs KOSPI 200

Performance Gap
207940 vs KOSPI 200

Performance By Year
207940 vs KOSPI 200

Competitors Performance
Samsung Biologics Co Ltd vs Peers

Samsung Biologics Co Ltd
Glance View